Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy

被引:16
|
作者
Cho, Hanhee [1 ,2 ]
Shim, Man Kyu [1 ]
Yang, Suah [1 ,3 ]
Song, Sukyung [1 ,4 ]
Moon, Yujeong [1 ,5 ]
Kim, Jinseong [1 ,3 ]
Byun, Youngro [6 ]
Ahn, Cheol-Hee [2 ]
Kim, Kwangmeyung [1 ,3 ]
机构
[1] Korea Inst Sci & Technol KIST, Biomed Res Inst, Seoul 02792, South Korea
[2] Seoul Natl Univ, Dept Mat Sci & Engn, Seoul 08826, South Korea
[3] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul 02841, South Korea
[4] Korea Univ, Dept Biosyst & Biotechnol, Seoul 02841, South Korea
[5] Korea Univ, Dept Bioengn, Seoul 02841, South Korea
[6] Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 08826, South Korea
基金
新加坡国家研究基金会;
关键词
prodrug; albumin; drug delivery; targeted therapy; chemotherapy; DRUG-DELIVERY;
D O I
10.3390/pharmaceutics14010083
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed to a short half-life and low tumor targeting. Herein, we propose cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug, Al-ProD, that consists of a albumin-binding maleimide group, cathepsin B-cleavable peptide (FRRG), and doxorubicin. The Al-ProD binds to in situ albumin, and albumin-bound Al-ProD indicates high tumor accumulation with prolonged half-life, and selctively releases doxorubicin in cathepsin B-overexpressed tumor cells, inducing a potent antitumor efficacy. Concurrently, toxicity of Al-ProD toward normal tissues with innately low cathepsin B expression is significantly reduced by maintaining an inactive state, thereby increasing the safety of chemotherapy. This study offers a promising approach for effective and safe chemotherapy, which may open new avenues for drug design and translational medicine.
引用
收藏
页数:13
相关论文
共 37 条
  • [1] In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
    Khalid Abu Ajaj
    Ralph Graeser
    Iduna Fichtner
    Felix Kratz
    Cancer Chemotherapy and Pharmacology, 2009, 64
  • [2] In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
    Abu Ajaj, Khalid
    Graeser, Ralph
    Fichtner, Iduna
    Kratz, Felix
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 413 - 418
  • [3] In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
    Abu Ajaj, Khalid
    Graeser, Ralph
    Fichtner, Iduna
    Kratz, Felix
    CANCER RESEARCH, 2009, 69
  • [4] An albumin-binding lidamycin prodrug for efficient targeted cancer therapy
    Hong, Han-Yu
    Zheng, Yi-Jia
    Li, Yu-Jing
    Dong, Yan-Qun
    Zhang, Jun-Yi
    Lv, Xing
    Zhao, Chun-Yan
    Zhen, Yong-Su
    Gong, Jian-Hua
    Cai, Lin
    Zheng, Yan-Bo
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 91
  • [5] Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin
    Abu Ajaj, Khalid
    Graeser, Ralph
    Kratz, Felix
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 117 - 129
  • [6] Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin
    Khalid Abu Ajaj
    Ralph Graeser
    Felix Kratz
    Breast Cancer Research and Treatment, 2012, 134 : 117 - 129
  • [7] Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy
    Cheng, Zhiyang
    Huang, Ying
    Shao, Pingxuan
    Wang, Lei
    Zhu, Shulei
    Yu, Jiahui
    Lu, Wei
    ACS OMEGA, 2022, 7 (01): : 1082 - 1089
  • [8] Albumin-binding doxorubicin prodrug selectively activated by radiation-induced apoptotic tumor cells
    Chung, Seung Woo
    Kim, Kwangmeyung
    Kim, Seong Who
    Kim, In-San
    Kim, Sang Yoon
    Byun, Youngro
    CANCER RESEARCH, 2016, 76
  • [9] Design, synthesis, and biological evaluation of cathepsin B cleavage albumin-binding SN38 prodrug in breast cancer
    Lu, Yingxin
    Huang, Ying
    Jin, Jiyu
    Yu, Jiahui
    Lu, Wei
    Zhu, Shulei
    BIOORGANIC CHEMISTRY, 2024, 147
  • [10] SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy
    Huang, Ying
    Wang, Lei
    Cheng, Zhiyang
    Yang, Biyu
    Yu, Jiahui
    Chen, Yi
    Lu, Wei
    JOURNAL OF CONTROLLED RELEASE, 2021, 339 : 297 - 306